CHICAGO MEDICAL RESEARCH, LLC.

Name: Suhail H. Khadra, MD, FACC, FSCAI

Email: skhadra@cmrllc1.com

PROFESSIONAL EMPLOYMENT:

2021 - Present	Medical Director and Principal Investigator, Chicago Medical Research, LLC, Hazel Crest, Illinois
2015 - Present	Cardiologist, Cardiovascular Consultants, Munster, Indiana
2014 - 2015	Cardiologist, Fullerton Heart Center, Chicago, Illinois
2000 - 2014	Director, Cardiac Catheterization Laboratory, Cook County Health, Chicago, Illinois
2010 - 2012	Acting Chairman, Division of Cardiology, Cook County Health, Chicago, Illinois
2000 - 2014	Chairman, Cardiovascular Subcommittee, Cook County Health, Chicago, Illinois

EDUCATION:

1973 - 1979	Doctor of Medicine, Damascus University School of Medicine, Damascus, Syria
1981 - 1982	Internship in Internal Medicine, Cook County Hospital, Chicago, Illinois
1981 - 1985	Residency in Internal Medicine, Cook County Hospital, Chicago, Illinois
	Fellowship in Cardiology, Cook County Hospital, Chicago, Illinois

LICENSE:

American Board of Internal Medicine - Internal Medicine, 1985
American Board of Internal Medicine - Cardiovascular Disease, 1987
American Board of Internal Medicine - Interventional Cardiology, 1999 and 2009-2019
ECFMG Certification - Certificate No. 304-514-3

HOSPITAL PRIVILEGES:

- Franciscan Health St. Margaret Mercy, South Campus, Dyer, Indiana - Active staff privileges.

PUBLICATIONS:

1. Liu KJ, Havelka G, Khadra S. Perioperative myocardial infarction in a patient with metabolic syndrome. Journal of Diabetes and Its Complications. 2007;21(6):350-352.
2. Gupta A, Drell MJ, Khadra S, Calvin JE. Management of unstable angina. Critical Pathways in Cardiology. 2002;1(4):218-222.
3. Abusin S, Bhimaraj A, Khadra S. Bacillus cereus endocarditis in a permanent pacemaker: a case report. Cases Journal. 2008;1(1):95.
4. Napan S, Kashinath R, Orig M, Kadri S, Khadra S. Racial difference in cardiovascular outcomes following percutaneous coronary intervention in a public health service patient population. Journal of Invasive Cardiology. 2010;22(4):168-173.
5. Napan S, Kashinath RC, Kadri S, Orig MN, Khadra S. Prognostic significance of preprocedural troponin-I in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. Coronary Artery Disease. 2010;21(5):361-365.
6. Medical Therapeutics. Damascus University, Ministry of Higher Education.
7. Goodman SG, et al. The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. American Heart Journal. 2009.
8. Tricoci P, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. New England Journal of Medicine. 2012;366(1):20-33.
9. Mathew J, Krishna A, Khadra S. Clinical and angiographic findings in Black patients with suspected coronary artery disease. International Journal of Cardiology. 1997;62(3):251-257.

PROFESSIONAL MEMBERSHIPS:

- Fellow, American College of Cardiology (FACC)
- Fellow, Society for Cardiovascular Angiography & Interventions (FSCAI)
- American Medical Association
- Syrian American Medical Society
- National Arab American Medical Association

SELECTED HONORS AND AWARDS:

- Distinguished Service Award, Lincoln West Hospital (1991)
- Castle Connolly Chicago Top Doctors (1999, 2000, 2001, 2002, 2009, 2011, 2012)
- Nominated for Teacher of the Year, Internal Medicine, Cook County Hospital/Rush (2000, 2001)
- Patients' Choice Award (2008, 2009, 2010, 2011, 2012)
- Chicago Magazine, Chicago Top Doctors (2009, 2012)
- U.S. News & World Report, America's Top Doctors (2009)
- Syrian American Medical Society Lifetime Teacher Award (2010)
- Vitals Top Ten Doctors (2012)

CLINICAL TRIAL EXPERIENCE

1. **Protocol: 70033093AFL3002 (LIBREXIA-AF)** - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation

2. **Protocol: 1378-0020 (EASi-HF Preserved)** - A Phase III Double-Blind, Randomised, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) >=40%.

3. **Protocol: EX6018-4758 (ZEUS)** - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation.

4. **Protocol: EX6018-4914 (ATHENA)** - Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

5. **Protocol: EX6018-4915 (HERMES)** - Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation.

6. **Protocol: D6402C00012 (BalanceD-HF)** - A Phase III, Randomised, Double-Blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function.

7. **Protocol: D6972C00003 (ARCTIC)** - A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

8. **Protocol: CV0291001 (BMS-986435/MYK-224 HFpEF)** - A Phase 2A, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF).

9. **Protocol: C4291003 (BRANCH-HF)** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948, in Adults With Heart Failure.

10. **Protocol: ALN-AGT01-008 / US0006 (ZENITH)** A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease.

11. **Protocol: 20230227 (MARITIME-HF)** - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity.

12. **Protocol: VS-041-102 (VS-041 HFpEF)** A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF).

13. **Protocol: NN9490-8266 (POLARIS) -** Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS)

14. **Protocol: NN9490-8665** - Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
15. **Protocol: D9480C00018 (REALIZE) -** Double-Blind, Placebo-Controlled Evaluation of Sodium Zirconium Cyclosilicate for the Management of Hyperkalemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.

16. **Protocol: STEP-HFpEF** - DM Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Participants With Obesity-Related Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes.

17. **Protocol: STEP-HFpEF** - Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Participants With Obesity-Related Heart Failure With Preserved Ejection Fraction.

18. **Protocol: Care-K-HK** in HF Registry Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or at High Risk of Hyperkalemia.

19. **Protocol: CREDO** - Clopidogrel for Reduction of Events During Observation: A Randomized Multicenter Study of Clopidogrel Plus Aspirin Versus Placebo Plus Aspirin in Patients Undergoing Angioplasty. - Co-Investigator.

20. **Protocol: PEACE -** Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy: A Randomized Multicenter Study of an ACE Inhibitor on Cardiac Mortality and Morbidity in Patients With Coronary Artery Disease.

21. **Protocol: HOPE -** Heart Outcomes Prevention Evaluation: A Randomized, Double-Blind, Multicenter Trial to Evaluate the Effect of an ACE Inhibitor on Cardiovascular Mortality and Morbidity in Patients at High Cardiovascular Risk.

22. **Protocol: CRUSADE Trial** at Cook County Hospital.

23. **Protocol: EARLY ACS** - Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial.

24. **Protocol: RED-HF** - A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure Participants With Symptomatic Left Ventricular Systolic Dysfunction and Anemia.

25. **Protocol: TRACER** - Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome.

26. **Protocol: SOLSTICE** - Study of Losmapimod Treatment on Inflammation and Infarct Size.

27. **Protocol: TRANSLATE-ACS** - A Study of In-Hospital and Longitudinal Outcomes of Acute Coronary Syndrome Patients Managed With Percutaneous Coronary Intervention, Including Post-Discharge Care Patterns and Treatment Adherence.

28. **Protocol: TAO** - A Double-Blind, Triple-Dummy Trial Comparing Otamixaban With Unfractionated Heparin Plus Eptifibatide in Patients With Unstable Angina or Non-ST-Elevation Myocardial Infarction Scheduled for an Early Invasive Strategy.

29. **Protocol: CIRT trial** (cardiovascular Inflammation reduction Trial) at Cook County Hospital.


30. **Protocol: 70033093AFL0001 -** Janssen Atrial Fibrillation Preference Survey A Non-Interventional Survey Study on the Preferences of Patients With Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes.

31. **Protocol: CRD-750-202** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction.

32. **Protocol: CRD-750-201** - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction.

33. **Protocol: 1378-0018 (BI-Reduced)** - EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%

SIGNATURE & DATE:



_____